| abstract |
Disclosed is a controlled release pharmaceutical composition that includes (R)-2-(2-aminothiazole-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl}acetanilide or a pharmaceutically acceptable salt thereof, and a sustained release pharmaceutical composition carrier, wherein the maximum blood drug concentration (Cmax) during administration under fasting conditions is no more than 400 ng/mL. |